Pragmatic management of progressive disease in idiopathic pulmonary fibrosis: a randomized trial. PROGRESSION-IPF
This research, called PROGRESSION-IPF, is looking into the best ways to manage a lung condition called Idiopathic Pulmonary Fibrosis (IPF). IPF causes scarring in the lungs, making it harder to breathe. This study compares two medicines, Esbriet and Ofev, that are already used to treat IPF. Researchers want to see if one medicine slows down the disease more effectively than the other over 24 weeks. They will also look at how well people tolerate the medicines and if they can stick with the treatment. The main goal is to understand which treatment approach is more helpful for patients with progressive IPF and to improve how we care for people with this condition. This is a large-scale study, aiming to confirm findings from earlier research.
At a glance
What is this study about?
This research study, called PROGRESSION-IPF, is investigating how to best manage Idiopathic Pulmonary Fibrosis (IPF). IPF is a serious lung disease where scar tissue builds up in your lungs, making them stiff and increasingly difficult to breathe. It's called 'idiopathic' because doctors don't know why it happens.
The study is specifically looking at what happens when IPF gets worse, or 'progresses'. It compares two common medicines, Esbriet and Ofev, which are already approved to treat IPF. The main aim is to see how much each medicine can slow down the decline in lung function over 24 weeks. This is important because managing IPF effectively can help people breathe better and maintain their quality of life.
By comparing these two well-known treatments, researchers hope to find clearer answers about which approach is most helpful for patients whose IPF is progressing. Understanding this better could lead to improved recommendations for doctors and better care for people living with IPF in the future. This type of study is often the final step before new treatment approaches are widely accepted.
Key takeaways
- This study compares two common IPF medicines, Esbriet and Ofev.
- It aims to find out which medicine best slows down lung scarring.
- You would receive one of these medicines, chosen by chance.
- Your lung function will be checked regularly over 24 weeks.
- The study helps doctors understand the best ways to treat IPF that is getting worse.
Who may be eligible?
To join this study, you must be at least 18 years old. There is no upper age limit, meaning older adults can also take part if they meet the other requirements. Both men and women are welcome to be considered for the study.
Detailed and specific medical requirements will be checked by the study doctors. These will make sure the study is right for you, and that it's safe for you to take part. For example, you would need to have been diagnosed with Idiopathic Pulmonary Fibrosis that is considered to be getting worse despite current treatments.
It's important to discuss your full medical history with the study team to confirm if you are suitable. They will also check if any other health conditions or medicines you are currently taking might affect your participation.
- Are you at least 18 years old?
- Have you been diagnosed with Idiopathic Pulmonary Fibrosis (IPF)?
- Is your IPF considered to be getting worse, even with current treatment?
- Are you able to attend regular hospital appointments for lung function tests?
- Are you willing to take study medication daily as prescribed?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you join the study, you would be randomly assigned to take either Esbriet tablets or Ofev capsules. This means that neither you nor your doctor will get to choose which medicine you receive; it's decided by chance, like flipping a coin. You would take this study medicine regularly as prescribed.
Over 24 weeks, you would have several visits to the hospital. At these visits, doctors will measure your lung function using a 'spirometry' test – a simple breathing test where you blow into a machine. This test will be done at the start of the study, and then again at week 4, week 12, and week 24. These measurements help the doctors see how well your lungs are working and if they are changing over time. You would also be monitored for side effects and how well you tolerate the medicine.
Potential risks and benefits
Locations (1)
- —France
Common questions
What is Idiopathic Pulmonary Fibrosis (IPF)?
IPF is a serious lung disease where scar tissue builds up in your lungs, making them stiff and making it harder to breathe. The word 'idiopathic' means we don't know the exact cause.
What are Esbriet and Ofev?
Esbriet and Ofev are two medicines that are already approved and commonly used to treat IPF. They work by trying to slow down the scarring process in the lungs.
Why is this study important?
This study aims to compare Esbriet and Ofev to see which one might be better at slowing down the progression of IPF and how well people tolerate them, helping doctors make better treatment choices.
What does 'randomised' mean in this study?
Randomised means that you will be put into a group to receive either Esbriet or Ofev by chance, like drawing lots. This helps make sure the study results are fair and unbiased.
How long will I be in the study?
The main part of the study where your lung function is measured will last for 24 weeks, which is about six months. You will have regular hospital visits during this time.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.